172 related articles for article (PubMed ID: 16959246)
21. Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
Kreft A; Springer E; Lipka DB; Kirkpatrick CJ
Acta Haematol; 2009; 122(1):36-8. PubMed ID: 19713696
[TBL] [Abstract][Full Text] [Related]
22. A novel cytogenetic abnormality in primary myelofibrosis.
Bae SY; Kim JS; Lee KN; Lee CK; Kim YK; Yoon SY; Lim CS; Cho YJ; Choi CW; Kim WY
Cancer Genet Cytogenet; 2009 Oct; 194(1):65-6. PubMed ID: 19737657
[No Abstract] [Full Text] [Related]
23. New insights into the pathogenesis and drug treatment of myelofibrosis.
Tefferi A
Curr Opin Hematol; 2006 Mar; 13(2):87-92. PubMed ID: 16456374
[TBL] [Abstract][Full Text] [Related]
24. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
25. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
26. Cytogenetic and clinical studies of a male infant with disorder of sexual development: case report.
Balkan M; Duran H; Onen A; Oral D; Isi H; Fidanboy M; Alp MN; Budak T
Fertil Steril; 2008 Nov; 90(5):2003.e13-6. PubMed ID: 18691707
[TBL] [Abstract][Full Text] [Related]
27. Identification of breakpoint cluster regions at 1p36.3 and 3q21 in hematologic malignancies with t(1;3)(p36;q21).
Shimizu S; Suzukawa K; Kodera T; Nagasawa T; Abe T; Taniwaki M; Yagasaki F; Tanaka H; Fujisawa S; Johansson B; Ahlgren T; Yokota J; Morishita K
Genes Chromosomes Cancer; 2000 Mar; 27(3):229-38. PubMed ID: 10679911
[TBL] [Abstract][Full Text] [Related]
28. Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status.
Bock O; Neuse J; Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H
Am J Pathol; 2006 Aug; 169(2):471-81. PubMed ID: 16877349
[TBL] [Abstract][Full Text] [Related]
29. Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9.
Bennour A; Sennana H; Laatiri MA; Elloumi M; Khelif A; Saad A
Cancer Genet Cytogenet; 2009 Oct; 194(1):30-7. PubMed ID: 19737651
[TBL] [Abstract][Full Text] [Related]
30. Translocation t(3;12)(q26;q21) in JAK2(V617F) Point Mutation Negative Chronic Idiopathic Myelofibrosis: A Case Report.
Mešanović S; Šahović H; Perić M
Balkan J Med Genet; 2014 Jun; 17(1):63-8. PubMed ID: 25741217
[TBL] [Abstract][Full Text] [Related]
31. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
Kodali S; Chen C; Rathnasabapathy C; Wang JC
Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
[TBL] [Abstract][Full Text] [Related]
32. [The application of fluorescence in situ hybridization in detecting chronic myeloid leukemia].
Qiu HR; Miao KR; Wang R; Qiao C; Zhang JF; Zhang SJ; Qian SX; Xu W; Li JY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):207-10. PubMed ID: 19350518
[TBL] [Abstract][Full Text] [Related]
33. Recurrent chromosomal aberration at 12q15 in chronic idiopathic myelofibrosis with or without JAK2(V617F) mutation.
Ohyashiki K; Tauchi T; Kuroda M; Kodama A; Ohyashiki JH
Leukemia; 2007 Jul; 21(7):1578-80. PubMed ID: 17443223
[No Abstract] [Full Text] [Related]
34. Fluorescence in situ hybridization dissection of a chronic myeloid leukemia case bearing the apparently balanced translocations (9;22)(q34;q11.2) and (11;11)(p15;q13).
Malvestiti F; Colombo D; Perego D; Rodeschini O; Finelli P; Larizza L; Giardino D
Cancer Genet Cytogenet; 2009 Jan; 188(1):42-7. PubMed ID: 19061779
[TBL] [Abstract][Full Text] [Related]
35. Molecular cytogenetic detection of 9q34 breakpoints associated with nail patella syndrome.
Silahtaroglu A; Hol FA; Jensen PK; Erdel M; Duba HC; Geurds MP; Knoers NV; Mariman EC; Tümer Z; Utermann G; Wirth J; Bugge M; Tommerup N
Eur J Hum Genet; 1999 Jan; 7(1):68-76. PubMed ID: 10094193
[TBL] [Abstract][Full Text] [Related]
36. Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance.
McDevitt MA; Condon M; Stamberg J; Karp JE; McDiarmid M
Mutat Res; 2007 Apr; 629(1):24-31. PubMed ID: 17276720
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.
Tang G; Sydney Sir Philip JK; Weinberg O; Tam W; Sadigh S; Lake JI; Margolskee EM; Rogers HJ; Miranda RN; Bueso-Ramos C C; Hsi ED; Orazi A; Hasserjian RP; Arber DA; Bagg A; Wang SA
Mod Pathol; 2019 Apr; 32(4):490-498. PubMed ID: 30401948
[TBL] [Abstract][Full Text] [Related]
38. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients.
Djordjevic V; Dencic-Fekete M; Jovanovic J; Bizic S; Jankovic G; Bogdanovic A; Cemerikic-Martinovic V; Gotic M
Cancer Genet Cytogenet; 2007 Feb; 173(1):57-62. PubMed ID: 17284371
[TBL] [Abstract][Full Text] [Related]
39. Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes.
Etienne A; Carbuccia N; Adélaïde J; Bekhouche I; Rémy V; Sohn C; Sainty D; Gastaut JA; Olschwang S; Birnbaum D; Mozziconacci MJ; Chaffanet M
Cancer Genet Cytogenet; 2007 Jul; 176(1):80-8. PubMed ID: 17574970
[TBL] [Abstract][Full Text] [Related]
40. Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis.
Andrieux J; Roche-Lestienne C; Geffroy S; Desterke C; Grardel N; Plantier I; Selleslag D; Demory JL; Laï JL; Leleu X; Le Bousse-Kerdiles C; Vandenberghe P
Cancer Genet Cytogenet; 2007 Oct; 178(1):11-6. PubMed ID: 17889703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
